| | Introduction
Bipolar disorder represents an important growth opportunity for olanzapine (Zyprexa) – arguably the most important product of a company (Lilly) that seeks to retain its longstanding role as the leading company in psychiatry. Lilly has expanded the initial indications for olanzapine as treatment for mania in the USA and Europe to also include long-term prophylaxis and the treatment of bipolar depression (in combination with fluoxetine). This is part of their attempt to position the drug as a useful therapy across the spectrum of mood and psychotic disorders.
| | 
More product adverts
General links
Product specific:
* = Internet link | |
